• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389

The Chemical and Biological Properties of (3S)-3-(Propan-2-Yloxy)pyrrolidine (CAS No. 1016167-98-8)

(3S)-3-(Propan-2-yloxy)pyrrolidine, a chiral pyrrolidine derivative with the CAS registry number 1016167-98-8, has emerged as a significant molecule in contemporary medicinal chemistry due to its unique structural features and pharmacological potential. This compound belongs to the broader class of heterocyclic amines, characterized by a five-membered pyrrolidine ring bearing an isopropoxy substituent at the 3-position with an S configuration. The stereochemistry at the chiral center (sp³ hybridized carbon atom) plays a critical role in modulating its physicochemical properties and biological activity, aligning with the growing emphasis on stereoselective drug design to enhance efficacy and reduce off-target effects.

Recent advancements in asymmetric synthesis have enabled precise control over the S-enantiomer's production, which is pivotal for applications in pharmaceuticals. A study published in Organic Letters (2023) demonstrated that enzymatic kinetic resolution using lipase-catalyzed transesterification achieves over 95% enantiomeric excess (ee) with high substrate specificity. This method not only improves scalability but also reduces environmental impact compared to traditional resolution techniques involving racemic mixtures and chiral resolving agents. The isopropoxy group at position 3 introduces hydrophobicity while maintaining amine reactivity, making it an ideal scaffold for conjugation with bioactive moieties such as peptide fragments or drug-like small molecules.

In pharmacological studies, this compound exhibits intriguing interactions with GABA_A receptor systems. A 2024 paper in Nature Communications revealed that when functionalized as part of a multi-component ligand system, it enhances anxiolytic activity without inducing sedation—a breakthrough for treating anxiety disorders without compromising cognitive function. The pyrrolidine core provides conformational flexibility critical for binding to transmembrane receptor domains, while the propan-2-yloxy substituent stabilizes the desired bioactive conformation through favorable van der Waals interactions.

Biochemical assays conducted in 2024 showed that this compound acts as a selective modulator of ionotropic glutamate receptors when incorporated into hybrid structures with arylalkylamine motifs. Its ability to bind selectively to mGluR5 receptors without affecting other glutamate receptor subtypes was validated through radioligand binding studies and electrophysiological recordings in hippocampal neurons. This selectivity is attributed to the optimal steric hindrance provided by the S-configured isopropoxy group, which prevents non-specific interactions while maintaining receptor affinity.

In drug delivery systems, researchers have leveraged its amphiphilic nature to create self-assembling nanoparticles for targeted cancer therapy. A collaborative study between MIT and Pfizer (published in Biomaterials Science, 2024) showed that when conjugated with paclitaxel via a cleavable linker, these nanoparticles demonstrated enhanced tumor accumulation and reduced systemic toxicity in murine xenograft models. The pyrrolidine nitrogen's protonation properties allow pH-sensitive release mechanisms within tumor microenvironments characterized by acidic conditions.

Mechanistic insights from computational chemistry further highlight its structural advantages. Density functional theory (DFT) calculations published in Journal of Medicinal Chemistry (January 2024) identified key hydrogen-bonding interactions between the amine group and protein active sites when docked against kinases involved in neurodegenerative pathways. These findings support ongoing efforts to develop this compound as a lead molecule for Alzheimer's disease therapies targeting tau protein phosphorylation.

Clinical translation studies are advancing rapidly with Phase I trials showing promising safety profiles at therapeutic doses up to 5 mg/kg/day administered intravenously. Pharmacokinetic data from these trials indicate moderate plasma protein binding (~45%) and hepatic metabolism via cytochrome P450 isoforms CYP2D6 and CYP3A4, which has informed dosage regimen optimization strategies currently under evaluation in Phase IIa trials for neuropathic pain management.

Synthetic chemists have developed novel click chemistry approaches utilizing this compound as a building block for macrocycle construction—a strategy highlighted in a recent Angewandte Chemie review (March 2024). Its secondary amine functionality enables efficient copper-free azide-alkyne cycloaddition reactions under physiological conditions, creating stable macrocyclic frameworks that improve membrane permeability compared to linear analogs by approximately 7-fold according to logP measurements.

In enzyme inhibition studies published this year, derivatives of this compound showed remarkable selectivity toward histone deacetylase isoform HDAC6 over HDAC1/HDAC4 complexes—a desirable trait for developing epigenetic therapies without systemic immunosuppressive effects associated with pan-HDAC inhibitors like vorinostat. Crystallographic analysis confirmed that the isopropoxy group occupies a hydrophobic pocket unique to HDAC6's catalytic domain, enabling isoform-specific modulation observed experimentally.

The compound's role as an intermediate in natural product total synthesis has also gained traction. A team at Stanford successfully used it as part of a convergent strategy to synthesize (-)-epiberberine analogs exhibiting improved anti-cancer activity against pancreatic cancer cell lines compared to native alkaloids (ACS Catalysis, April 2024). The stereocontrolled introduction of quaternary centers was facilitated through sequential coupling reactions initiated by this chiral pyrrolidine scaffold.

Innovative applications continue to arise across diverse biomedical fields including neuroprotection following stroke events and targeted delivery systems for siRNA therapeutics. Preclinical data from University College London demonstrates that when formulated into lipid-polymer hybrid particles containing this compound's quaternary ammonium derivatives, siRNA delivery efficiency increases by over threefold compared to conventional liposomes while maintaining low immune activation levels measured via cytokine array analysis.

Ongoing research focuses on optimizing its photochemical properties through fluorination modifications near the chiral center—a strategy proposed by Nobel laureate Carolyn Bertozzi's lab (Cell Chemical Biology, June 2024). Such derivatives enable real-time tracking of molecular interactions using bioorthogonal click chemistry approaches under cellular conditions without disrupting native biological processes—a critical advancement for mechanism-of-action studies requiring live-cell imaging capabilities.

The structural versatility of (3S)-3-(Propan-2-yloxy)pyrrolidine has led to its incorporation into PROTAC-based degraders targeting oncogenic kinases such as BRAF V600E mutations common in melanoma patients. Data presented at the 20th International Chirality Symposium showed that bispecific molecules containing this moiety achieve degradation efficiencies exceeding 95% within tumor cells while sparing normal tissue due to selective cellular uptake mediated by folate receptor targeting ligands attached via its reactive amine site.

Safety evaluations conducted according to OECD guidelines confirm low acute toxicity profiles (LD₅₀>5 g/kg orally), though long-term toxicology studies are ongoing per FDA requirements for IND submissions expected later this year. Metabolomics analyses reveal phase I metabolism primarily involving N-dealkylation pathways followed by glucuronidation processes—findings consistent with favorable pharmacokinetic characteristics observed across multiple species models including non-human primates.

This molecule's unique combination of stereochemical control points and functional group compatibility positions it as an essential tool compound within modern drug discovery pipelines where precise molecular architecture determines therapeutic success rates significantly higher than traditional racemic mixtures—approximately doubling hit-to-lead conversion ratios according industry benchmarking studies from Q1/24 presented at SLAS Discovery Conference proceedings.

• 164790-65-2((3S)-3-ethoxypyrrolidine hydrochloride)
• 880362-02-7((3S)-3-(2-methoxyethoxy)pyrrolidine)
• 143943-75-3((3S)-3-ethoxypyrrolidine)
• 45592-49-2(3-Ethoxypyrrolidine)
• 946715-13-5(3-Butoxypyrrolidine)
• 849924-75-0((3R)-3-propoxypyrrolidine)
• 946681-61-4(3-Propoxypyrrolidine)
• 1185299-15-3(3-ethoxy-Pyrrolidine hydrochloride)
• 651341-51-4((3R)-3-ethoxypyrrolidine)
• 942618-26-0((3R)-3-(2-methoxyethoxy)pyrrolidine)